特应性皮炎中嗜碱性粒细胞活性:度普利尤单抗与阿布昔替尼的免疫调节作用差异
本研究探讨度普利尤单抗和阿布昔替尼对特应性皮炎(AD)患者嗜碱性粒细胞活化的影响。AD患者循环嗜碱性粒细胞计数升高,FcεRIα、MRGPRX2和CD63表达增加,皮损中可检测到MRGPRX2阳性嗜碱性粒细胞。两药均改善症状但作用不同:度普利尤单抗选择性降低MRGPRX2,阿布昔替尼优先下调CD203c,基线CD63与阿布昔替尼临床反应相关。
要点
- AD患者嗜碱性粒细胞计数升高且FcεRIα、MRGPRX2、CD63表达增加。
- 度普利尤单抗选择性降低MRGPRX2,阿布昔替尼优先下调CD203c。
- 基线CD63表达与阿布昔替尼临床反应相关,MRGPRX2或为治疗反应生物标志物。
核心结论
- 靶向治疗对AD嗜碱性粒细胞高活性具有差异化调节作用,嗜碱性粒细胞是关键效应细胞,MRGPRX2是有前景的治疗反应生物标志物。
研究设计与样本
- 采用流式细胞术、离体刺激实验和免疫荧光分析,比较AD患者与健康对照的嗜碱性粒细胞活化,并评估度普利尤单抗和阿布昔替尼的影响。
主要发现
- AD患者循环嗜碱性粒细胞计数升高,FcεRIα、MRGPRX2和CD63表达增加。
- 皮损AD皮肤中检测到MRGPRX2阳性嗜碱性粒细胞,离体刺激后进一步上调。
- 度普利尤单抗选择性降低MRGPRX2表达,阿布昔替尼优先下调CD203c。
- 基线嗜碱性粒细胞CD63表达与阿布昔替尼临床反应相关。
- AD患者嗜碱性粒细胞经N-甲酰-Met-Leu-Phe或抗IgE刺激后MRGPRX2显著上调,健康对照无此现象;度普利尤单抗选择性抑制N-甲酰-Met-Leu-Phe诱导的MRGPRX2上调而不影响IgE介导的诱导,阿布昔替尼抑制所有刺激引起的上调。
临床怎么用
- 度普利尤单抗和阿布昔替尼均改善AD症状但对嗜碱性粒细胞作用不同,临床选择靶向药物时可考虑其对嗜碱性粒细胞活化的差异化影响。
- 基线嗜碱性粒细胞CD63表达可能有助于预测阿布昔替尼临床反应。
- MRGPRX2可作为AD治疗反应生物标志物进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Basophils are increasingly recognized as key contributors to the pathogenesis of atopic dermatitis (AD), yet how targeted therapies modulate their phenotype and function remains poorly defined. We investigated the effects of dupilumab and abrocitinib on basophil activation in AD using flow cytometry, ex vivo stimulation assays, and immunofluorescence analysis. Compared with healthy controls, patients with AD showed elevated circulating basophil counts and increased expression of FcεRIα, MRGPRX2, and CD63. MRGPRX2-expressing basophils were also detected in lesional AD skin and exhibited further upregulation upon ex vivo stimulation. Both dupilumab and abrocitinib improved clinical symptoms, but their effects on basophils diverged. Dupilumab selectively reduced MRGPRX2 expression, whereas abrocitinib preferentially downregulated CD203c. Baseline CD63 expression on basophils correlated with clinical response to abrocitinib. Functional assays demonstrated that MRGPRX2 expression was significantly upregulated on basophils from patients with AD but not in healthy controls upon stimulation with N-formyl-Met-Leu-Phe or anti-IgE. Dupilumab selectively inhibited N-formyl-Met-Leu-Phe-induced MRGPRX2 upregulation without affecting IgE-mediated induction, whereas abrocitinib suppressed upregulation irrespective of the stimulus. These findings indicate that targeted therapies differentially modulate basophil hyperactivity, highlighting basophils as critical effector cells and MRGPRX2 as a promising biomarker for treatment response in AD.
引用
- Jiang W, Xie X, Yang S, et al. Basophil activity in atopic dermatitis: Distinct immunomodulatory roles of dupilumab and abrocitinib. J Invest Dermatol. 2026. PMID: 41812971. doi:10.1016/j.jid.2026.02.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。